Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children-Reference-Cited by-同舟云学术

Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children

Published:2023-12-13 Issue: Volume: Page:
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Nathan Nadia¹²^ORCID,Thouvenin Guillaume¹³,Dubern Béatrice⁴⁵^ORCID,Corvol Harriet¹³^ORCID

Affiliation:

1. Pediatric Pulmonology Department, Reference Center for Rare Lung Diseases RespiRare Armand Trousseau Hospital, Assistance Publique–Hôpitaux de Paris, Sorbonne Université Paris France

2. Inserm UMR_S933, Laboratory of Childhood Genetic Diseases Paris France

3. Centre de recherche Saint Antoine (CRSA) Paris France

4. Assistance Publique‐Hôpitaux de Paris French Reference Center for Prader‐Willi Syndrome and Other Rare Obesities (PRADORT) Paris France

5. Nutrition and Obesities: Systemic Approaches Research Unit (Nutriomics) Sorbonne Université, INSERM Paris France

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.26794

Reference7 articles.

1. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

2. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

3. Changes in fecal elastase‐1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis;Stephenson KG;J Cyst Fibros,2023

4. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele

5. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial